AU763446B2 - Methods, systems, and associated implantable devices for dynamic monitoring of tumors - Google Patents
Methods, systems, and associated implantable devices for dynamic monitoring of tumors Download PDFInfo
- Publication number
- AU763446B2 AU763446B2 AU62764/99A AU6276499A AU763446B2 AU 763446 B2 AU763446 B2 AU 763446B2 AU 62764/99 A AU62764/99 A AU 62764/99A AU 6276499 A AU6276499 A AU 6276499A AU 763446 B2 AU763446 B2 AU 763446B2
- Authority
- AU
- Australia
- Prior art keywords
- tumor
- treatment
- sensor
- sensor unit
- data
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 367
- 238000012544 monitoring process Methods 0.000 title claims abstract description 120
- 238000000034 method Methods 0.000 title claims abstract description 114
- 238000011282 treatment Methods 0.000 claims abstract description 236
- 230000005855 radiation Effects 0.000 claims abstract description 87
- 238000004590 computer program Methods 0.000 claims abstract description 39
- 230000002349 favourable effect Effects 0.000 claims abstract description 38
- 230000005540 biological transmission Effects 0.000 claims abstract description 37
- 238000011065 in-situ storage Methods 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 238000001727 in vivo Methods 0.000 claims abstract description 23
- 238000011269 treatment regimen Methods 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 72
- 229910052760 oxygen Inorganic materials 0.000 claims description 52
- 239000001301 oxygen Substances 0.000 claims description 52
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 51
- 238000012360 testing method Methods 0.000 claims description 48
- 238000006213 oxygenation reaction Methods 0.000 claims description 43
- 238000002560 therapeutic procedure Methods 0.000 claims description 39
- 230000004663 cell proliferation Effects 0.000 claims description 34
- 230000004044 response Effects 0.000 claims description 34
- 230000001965 increasing effect Effects 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 24
- 238000005259 measurement Methods 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 20
- 230000000875 corresponding effect Effects 0.000 claims description 19
- 230000001419 dependent effect Effects 0.000 claims description 19
- 210000004881 tumor cell Anatomy 0.000 claims description 18
- 238000004891 communication Methods 0.000 claims description 17
- 238000011156 evaluation Methods 0.000 claims description 17
- 206010021143 Hypoxia Diseases 0.000 claims description 16
- 230000008859 change Effects 0.000 claims description 16
- 238000012545 processing Methods 0.000 claims description 14
- 231100000433 cytotoxic Toxicity 0.000 claims description 13
- 230000001472 cytotoxic effect Effects 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 238000005516 engineering process Methods 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 10
- 230000000737 periodic effect Effects 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 8
- 238000011275 oncology therapy Methods 0.000 claims description 8
- 230000022131 cell cycle Effects 0.000 claims description 6
- 230000001146 hypoxic effect Effects 0.000 claims description 6
- 239000000560 biocompatible material Substances 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 230000003542 behavioural effect Effects 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims description 2
- 230000004962 physiological condition Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 238000013179 statistical model Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 35
- 239000000758 substrate Substances 0.000 description 25
- 239000007943 implant Substances 0.000 description 24
- 238000002512 chemotherapy Methods 0.000 description 17
- 238000013461 design Methods 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 230000008569 process Effects 0.000 description 16
- 230000003211 malignant effect Effects 0.000 description 15
- 238000001959 radiotherapy Methods 0.000 description 15
- 206010020843 Hyperthermia Diseases 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000036031 hyperthermia Effects 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 229940127089 cytotoxic agent Drugs 0.000 description 12
- 239000002254 cytotoxic agent Substances 0.000 description 12
- 231100000599 cytotoxic agent Toxicity 0.000 description 12
- 238000010586 diagram Methods 0.000 description 12
- 239000004642 Polyimide Substances 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 229920001721 polyimide Polymers 0.000 description 11
- 230000007954 hypoxia Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000006399 behavior Effects 0.000 description 9
- 239000003990 capacitor Substances 0.000 description 9
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000005868 electrolysis reaction Methods 0.000 description 8
- 239000010931 gold Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 206010073306 Exposure to radiation Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 7
- 229910052737 gold Inorganic materials 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- HTXDPTMKBJXEOW-UHFFFAOYSA-N dioxoiridium Chemical compound O=[Ir]=O HTXDPTMKBJXEOW-UHFFFAOYSA-N 0.000 description 5
- 229910000457 iridium oxide Inorganic materials 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- SJEFKIVIMJHMLR-UHFFFAOYSA-N oxomercury;zinc Chemical compound [Zn].[Hg]=O SJEFKIVIMJHMLR-UHFFFAOYSA-N 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 235000008119 Larix laricina Nutrition 0.000 description 3
- 241000218653 Larix laricina Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940030792 clinac Drugs 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000002555 ionophore Substances 0.000 description 3
- 230000000236 ionophoric effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229910000510 noble metal Inorganic materials 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 238000012307 MRI technique Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000018486 cell cycle phase Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000009713 electroplating Methods 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002977 hyperthermial effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001465 metallisation Methods 0.000 description 2
- FEBNTWHYQKGEIQ-BIMULSAOSA-N nardin Natural products C[C@H]1CC[C@H](C=C(/C)C(=O)O)C2=C(C)CC[C@@H]12 FEBNTWHYQKGEIQ-BIMULSAOSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000001029 thermal curing Methods 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000581444 Clinidae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- KZNMRPQBBZBTSW-UHFFFAOYSA-N [Au]=O Chemical compound [Au]=O KZNMRPQBBZBTSW-UHFFFAOYSA-N 0.000 description 1
- YFXWODPYUNGUEE-UHFFFAOYSA-N [I].[Li] Chemical compound [I].[Li] YFXWODPYUNGUEE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000513 bioprotective effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229910021397 glassy carbon Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000009217 hyperthermia therapy Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000001755 magnetron sputter deposition Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920002529 medical grade silicone Polymers 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- HTQOEHYNHFXMJJ-UHFFFAOYSA-N oxosilver zinc Chemical compound [Zn].[Ag]=O HTQOEHYNHFXMJJ-UHFFFAOYSA-N 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- UUWCBFKLGFQDME-UHFFFAOYSA-N platinum titanium Chemical compound [Ti].[Pt] UUWCBFKLGFQDME-UHFFFAOYSA-N 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000011849 radiological investigation Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000006903 response to temperature Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- BSWGGJHLVUUXTL-UHFFFAOYSA-N silver zinc Chemical compound [Zn].[Ag] BSWGGJHLVUUXTL-UHFFFAOYSA-N 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- FEBNTWHYQKGEIQ-UHFFFAOYSA-N valerenic acid Chemical compound CC1CCC(C=C(C)C(O)=O)C2=C(C)CCC12 FEBNTWHYQKGEIQ-UHFFFAOYSA-N 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 238000003631 wet chemical etching Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0031—Implanted circuitry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/417—Evaluating particular organs or parts of the immune or lymphatic systems the bone marrow
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/028—Microscale sensors, e.g. electromechanical sensors [MEMS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/08—Sensors provided with means for identification, e.g. barcodes or memory chips
- A61B2562/085—Sensors provided with means for identification, e.g. barcodes or memory chips combined with means for recording calibration data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1048—Monitoring, verifying, controlling systems and methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1048—Monitoring, verifying, controlling systems and methods
- A61N5/1071—Monitoring, verifying, controlling systems and methods for verifying the dose delivered by the treatment plan
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Chemical & Material Sciences (AREA)
- General Business, Economics & Management (AREA)
- Business, Economics & Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Computer Networks & Wireless Communication (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Radiation-Therapy Devices (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10244798P | 1998-09-30 | 1998-09-30 | |
| US60/102447 | 1998-09-30 | ||
| PCT/US1999/022638 WO2000018294A1 (en) | 1998-09-30 | 1999-09-29 | Methods, systems, and associated implantable devices for dynamic monitoring of tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6276499A AU6276499A (en) | 2000-04-17 |
| AU763446B2 true AU763446B2 (en) | 2003-07-24 |
Family
ID=22289894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU62764/99A Ceased AU763446B2 (en) | 1998-09-30 | 1999-09-29 | Methods, systems, and associated implantable devices for dynamic monitoring of tumors |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP1117328B1 (enExample) |
| JP (1) | JP4365531B2 (enExample) |
| AT (2) | ATE408369T1 (enExample) |
| AU (1) | AU763446B2 (enExample) |
| CA (1) | CA2341724C (enExample) |
| DE (2) | DE69943029D1 (enExample) |
| DK (2) | DK1117328T3 (enExample) |
| ES (1) | ES2316193T3 (enExample) |
| PT (1) | PT1117328E (enExample) |
| WO (1) | WO2000018294A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US20050103624A1 (en) | 1999-10-04 | 2005-05-19 | Bhullar Raghbir S. | Biosensor and method of making |
| US20010027384A1 (en) * | 2000-03-01 | 2001-10-04 | Schulze Arthur E. | Wireless internet bio-telemetry monitoring system and method |
| WO2005119025A2 (en) | 2004-06-01 | 2005-12-15 | Spectrum Dynamics Llc | Radioactive-emission-measurement optimization to specific body structures |
| US8909325B2 (en) | 2000-08-21 | 2014-12-09 | Biosensors International Group, Ltd. | Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures |
| WO2002039112A2 (en) | 2000-11-09 | 2002-05-16 | Sicel Technologies, Inc. | In vivo detection of biomolecule concentrations using fluorescent tags |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US7011814B2 (en) * | 2001-04-23 | 2006-03-14 | Sicel Technologies, Inc. | Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject |
| US7557353B2 (en) | 2001-11-30 | 2009-07-07 | Sicel Technologies, Inc. | Single-use external dosimeters for use in radiation therapies |
| AU2003210709B2 (en) | 2002-01-29 | 2007-12-06 | Sicel Technologies, Inc. | Implantable sensor housing and fabrication methods |
| US7736309B2 (en) * | 2002-09-27 | 2010-06-15 | Medtronic Minimed, Inc. | Implantable sensor method and system |
| US7244264B2 (en) | 2002-12-03 | 2007-07-17 | Roche Diagnostics Operations, Inc. | Dual blade lancing test strip |
| EP1578262A4 (en) | 2002-12-31 | 2007-12-05 | Therasense Inc | CONTINUOUS BLOOD SUGAR MONITORING SYSTEM AND USE METHOD |
| EP1594551A2 (en) | 2003-02-19 | 2005-11-16 | Sicel Technologies, Inc. | In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes |
| DK1618768T3 (da) * | 2003-04-15 | 2013-09-08 | Senseonics Inc | Implanterbar sensorbearbejdningssystem med integreret printkort-antenne |
| US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
| US9470801B2 (en) | 2004-01-13 | 2016-10-18 | Spectrum Dynamics Llc | Gating with anatomically varying durations |
| CN1981210A (zh) | 2004-01-13 | 2007-06-13 | 光谱动力学有限责任公司 | 多维图像重构 |
| US7968851B2 (en) | 2004-01-13 | 2011-06-28 | Spectrum Dynamics Llc | Dynamic spect camera |
| WO2008010227A2 (en) | 2006-07-19 | 2008-01-24 | Spectrum Dynamics Llc | Imaging protocols |
| CA2556331A1 (en) | 2004-02-17 | 2005-09-29 | Therasense, Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
| US7970455B2 (en) | 2004-05-20 | 2011-06-28 | Spectrum Dynamics Llc | Ingestible device platform for the colon |
| JP3950977B2 (ja) * | 2004-06-25 | 2007-08-01 | 国立大学法人東北大学 | 体内埋め込み型リアルタイム式マイクロ線量計装置ならびに測定方法 |
| US9943274B2 (en) | 2004-11-09 | 2018-04-17 | Spectrum Dynamics Medical Limited | Radioimaging using low dose isotope |
| US9316743B2 (en) | 2004-11-09 | 2016-04-19 | Biosensors International Group, Ltd. | System and method for radioactive emission measurement |
| DK1868498T3 (da) * | 2005-03-29 | 2013-06-03 | Martin Roche | Sensor til detektering af kropsparametre samt fremgangsmåde til detektering af kropsparametre |
| US20110213221A1 (en) | 2005-03-29 | 2011-09-01 | Roche Martin W | Method for Detecting Body Parameters |
| WO2006113394A2 (en) | 2005-04-15 | 2006-10-26 | Surgisense Corporation | Surgical instruments with sensors for detecting tissue properties, and systems using such instruments |
| US8837793B2 (en) | 2005-07-19 | 2014-09-16 | Biosensors International Group, Ltd. | Reconstruction stabilizer and active vision |
| US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
| US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
| US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
| US8894974B2 (en) | 2006-05-11 | 2014-11-25 | Spectrum Dynamics Llc | Radiopharmaceuticals for diagnosis and therapy |
| WO2008075362A2 (en) | 2006-12-20 | 2008-06-26 | Spectrum Dynamics Llc | A method, a system, and an apparatus for using and processing multidimensional data |
| US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
| US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
| US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
| SI1972275T1 (sl) * | 2007-03-20 | 2016-02-29 | F. Hoffmann-La Roche Ag | Sistem za merjenje koncentracije analita in vivo |
| US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
| US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| CN102209491B (zh) * | 2008-11-11 | 2016-03-30 | 皇家飞利浦电子股份有限公司 | 包括探针用于测量患者组织中的温度数据的医疗设备 |
| US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
| WO2010127050A1 (en) | 2009-04-28 | 2010-11-04 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
| US9184490B2 (en) | 2009-05-29 | 2015-11-10 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
| US8892185B2 (en) * | 2009-06-26 | 2014-11-18 | Cianna Medical, Inc. | Apparatus, systems, and methods for localizing markers or tissue structures within a body |
| EP2473098A4 (en) | 2009-08-31 | 2014-04-09 | Abbott Diabetes Care Inc | ANALYTICAL SIGNAL PROCESSING APPARATUS AND METHOD |
| WO2011026148A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
| US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
| JP6443802B2 (ja) | 2011-11-07 | 2018-12-26 | アボット ダイアベティス ケア インコーポレイテッドＡｂｂｏｔｔ Ｄｉａｂｅｔｅｓ Ｃａｒｅ Ｉｎｃ． | 分析物モニタリング装置および方法 |
| US9144489B2 (en) | 2012-06-13 | 2015-09-29 | Elwha Llc | Breast implant with covering, analyte sensors and internal power source |
| US8790400B2 (en) | 2012-06-13 | 2014-07-29 | Elwha Llc | Breast implant with covering and analyte sensors responsive to external power source |
| US8808373B2 (en) | 2012-06-13 | 2014-08-19 | Elwha Llc | Breast implant with regionalized analyte sensors responsive to external power source |
| US8795359B2 (en) | 2012-06-13 | 2014-08-05 | Elwha Llc | Breast implant with regionalized analyte sensors and internal power source |
| US9144488B2 (en) | 2012-06-13 | 2015-09-29 | Elwha Llc | Breast implant with analyte sensors responsive to external power source |
| US9211185B2 (en) | 2012-06-13 | 2015-12-15 | Elwha Llc | Breast implant with analyte sensors and internal power source |
| US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
| EP4079242B1 (en) | 2013-03-19 | 2025-10-08 | Surgisense Corporation | Apparatus, systems and methods for determining tissue oxygenation |
| JP6512623B2 (ja) * | 2014-02-07 | 2019-05-15 | 国立大学法人北海道大学 | 吸収線量測定システムおよび測定装置および方法 |
| CN107072505B (zh) | 2014-04-05 | 2021-03-12 | 手术感应设备公司 | 用于组织氧合的绘制的装置、系统和方法 |
| JP6385740B2 (ja) * | 2014-07-04 | 2018-09-05 | ルネサスエレクトロニクス株式会社 | 電子装置およびその製造方法 |
| CN104970806B (zh) * | 2015-07-12 | 2017-08-04 | 北京泱深生物信息技术有限公司 | 一种用于癌症复发实时动态监测的智能设备 |
| GB2566463A (en) * | 2017-09-13 | 2019-03-20 | Univ Southampton | pH Sensor and Calibration method |
| JP7325404B2 (ja) | 2017-09-13 | 2023-08-14 | ホロジック， インコーポレイテッド | 無線式能動的モニタリングインプラントシステム |
| SI25656A (sl) | 2018-06-01 | 2019-12-31 | Jože Abram | Mešalno brizgalna glava za tridimenzionalni tiskalnik za tiskanje sten zgradb in metoda tiskanja |
| WO2020181281A1 (en) * | 2019-03-07 | 2020-09-10 | Procept Biorobotics Corporation | Implant for continuous patient monitoring and intelligent treatment |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0420177A1 (de) * | 1989-09-28 | 1991-04-03 | ArguMens Mikrowellenelektronik GmbH | Vorrichtung zur drahtlosen Messung einer lokalen physikalischen Grösse |
| US5593430A (en) * | 1995-01-27 | 1997-01-14 | Pacesetter, Inc. | Bus system for interconnecting an implantable medical device with a plurality of sensors |
| WO1997033513A1 (en) * | 1996-03-13 | 1997-09-18 | Lipomatrix Incorporated | Implantable biosensing transponder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3219558C2 (de) * | 1982-05-25 | 1986-10-23 | Norbert H.L. Dr.-Ing. 5173 Aldenhoven Koster | Vorrichtung zur Bestimmung der lokalen Temperatur in lebendem Gewebe |
| JPS61146230A (ja) * | 1984-12-19 | 1986-07-03 | 東洋通信機株式会社 | 係止具を設けた生体内埋込みセンサ |
| JPS62102733A (ja) * | 1985-10-31 | 1987-05-13 | 東洋通信機株式会社 | 生体内温度検出表示装置 |
| IL86470A (en) * | 1988-05-23 | 1994-11-28 | E M T Electro Magnetic Technol | Means and method for temperature control from a distance |
| JP2762283B2 (ja) * | 1988-10-31 | 1998-06-04 | 東洋通信機株式会社 | 生体内埋め込みセンサ |
| US5791344A (en) | 1993-11-19 | 1998-08-11 | Alfred E. Mann Foundation For Scientific Research | Patient monitoring system |
| DE4341903A1 (de) * | 1993-12-09 | 1995-06-14 | Josef Prof Dr Rer Nat Binder | Implantierbares telemetrisches Endosystem |
| US5544661A (en) * | 1994-01-13 | 1996-08-13 | Charles L. Davis | Real time ambulatory patient monitor |
| US5720771A (en) | 1995-08-02 | 1998-02-24 | Pacesetter, Inc. | Method and apparatus for monitoring physiological data from an implantable medical device |
| EP0890117B1 (de) * | 1996-03-27 | 2002-01-02 | MedNetix AG | Vorrichtung und verfahren zur positionsbestimmung |
| US5814089A (en) * | 1996-12-18 | 1998-09-29 | Medtronic, Inc. | Leadless multisite implantable stimulus and diagnostic system |
| WO1998043701A1 (en) * | 1997-03-27 | 1998-10-08 | Alfred E. Mann Foundation For Scientific Research | System of implantable devices for monitoring and/or affecting body parameters |
| WO1998058250A2 (en) * | 1997-06-16 | 1998-12-23 | Elan Corporation, Plc | Methods of calibrating and testing a sensor for in vivo measurement of an analyte and devices for use in such methods |
| JP2000005136A (ja) * | 1998-06-26 | 2000-01-11 | Nippon Telegr & Teleph Corp <Ntt> | 温度測定装置およびインプラント |
| US9472410B2 (en) | 2014-03-05 | 2016-10-18 | Applied Materials, Inc. | Pixelated capacitance controlled ESC |
-
1999
- 1999-09-29 DK DK99950017T patent/DK1117328T3/da active
- 1999-09-29 AT AT99950017T patent/ATE408369T1/de active
- 1999-09-29 WO PCT/US1999/022638 patent/WO2000018294A1/en not_active Ceased
- 1999-09-29 JP JP2000571817A patent/JP4365531B2/ja not_active Expired - Lifetime
- 1999-09-29 ES ES99950017T patent/ES2316193T3/es not_active Expired - Lifetime
- 1999-09-29 EP EP99950017A patent/EP1117328B1/en not_active Expired - Lifetime
- 1999-09-29 AT AT07016983T patent/ATE490725T1/de not_active IP Right Cessation
- 1999-09-29 DK DK07016983.4T patent/DK1867275T3/da active
- 1999-09-29 EP EP07016983A patent/EP1867275B1/en not_active Expired - Lifetime
- 1999-09-29 PT PT99950017T patent/PT1117328E/pt unknown
- 1999-09-29 AU AU62764/99A patent/AU763446B2/en not_active Ceased
- 1999-09-29 CA CA2341724A patent/CA2341724C/en not_active Expired - Fee Related
- 1999-09-29 DE DE69943029T patent/DE69943029D1/de not_active Expired - Lifetime
- 1999-09-29 DE DE69939592T patent/DE69939592D1/de not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0420177A1 (de) * | 1989-09-28 | 1991-04-03 | ArguMens Mikrowellenelektronik GmbH | Vorrichtung zur drahtlosen Messung einer lokalen physikalischen Grösse |
| US5593430A (en) * | 1995-01-27 | 1997-01-14 | Pacesetter, Inc. | Bus system for interconnecting an implantable medical device with a plurality of sensors |
| WO1997033513A1 (en) * | 1996-03-13 | 1997-09-18 | Lipomatrix Incorporated | Implantable biosensing transponder |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1117328A1 (en) | 2001-07-25 |
| JP4365531B2 (ja) | 2009-11-18 |
| EP1117328B1 (en) | 2008-09-17 |
| DK1867275T3 (da) | 2011-04-04 |
| DE69943029D1 (de) | 2011-01-20 |
| DE69939592D1 (de) | 2008-10-30 |
| ES2316193T3 (es) | 2009-04-01 |
| ATE408369T1 (de) | 2008-10-15 |
| EP1867275A3 (en) | 2008-04-09 |
| AU6276499A (en) | 2000-04-17 |
| CA2341724A1 (en) | 2000-04-06 |
| WO2000018294A1 (en) | 2000-04-06 |
| CA2341724C (en) | 2010-12-21 |
| ATE490725T1 (de) | 2010-12-15 |
| DK1117328T3 (da) | 2009-01-19 |
| JP2002525153A (ja) | 2002-08-13 |
| EP1867275B1 (en) | 2010-12-08 |
| PT1117328E (pt) | 2008-12-02 |
| EP1867275A2 (en) | 2007-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU763446B2 (en) | Methods, systems, and associated implantable devices for dynamic monitoring of tumors | |
| US6402689B1 (en) | Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors | |
| CN102469964B (zh) | 分析物监测装置和使用方法 | |
| CN102472719B (zh) | 分析物监测装置和使用方法 | |
| US20140163338A1 (en) | Analyte Sensor with Slot Antenna | |
| JP2002513602A (ja) | 分析物モニタシステムおよびその使用方法 | |
| CN102469965A (zh) | 分析物监测装置和使用方法 | |
| US12426811B2 (en) | Detection of changes in patient health based on glucose data | |
| WO2022245804A1 (en) | Detection of changes in patient health based on glucose data | |
| EP3609404A1 (en) | Medical system | |
| Black et al. | Integrated sensor-telemetry system for in vivo glucose monitoring | |
| Jameson et al. | Data capture of transdermal glucose monitoring through computerized appliance-based virtual remote sensing and alert systems | |
| HK1181629A (en) | Analyte sensor having a slot antenna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND APPLICANT DETAIL TO READ SICEL TECHNOLOGIES, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |